Monitor for subsequent 8-K filings disclosing trial initiation, enrollment milestones, or financing updates. The Phase 2 start-up agreement is a procedural step; stock-moving catalysts will be data readouts or regulatory updates.
Price Chart
Executive Summary
Quantum BioPharma announced a Study Start-Up Agreement with Thermo Fisher's PPD clinical research business to initiate its Phase 2 trial of Lucid-MS (Lucid-21-302) for progressive multiple sclerosis. This operational milestone follows FDA clearance and moves the program toward clinical evaluation, but no financial terms, trial start date, or enrollment targets were disclosed.
Key Facts
- Quantum BioPharma entered a Study Start-Up Agreement with Thermo Fisher Scientific's PPD clinical research business for the Phase 2 trial of Lucid-MS.
- The Phase 2 trial is a randomized, double-blind, placebo-controlled study evaluating efficacy, safety, and tolerability in progressive multiple sclerosis.
- Lucid-MS is a first-in-class NCE targeting PAD2 to inhibit demyelination; preclinical data showed ability to prevent and reverse measures of myelin degradation.
- No financial terms, trial start date, enrollment size, or duration were disclosed in the press release.
- The MS therapeutic market is projected to exceed $38 billion by 2030 per Grand View Research.
Financial Impact
No financial terms disclosed; deal value not stated.
Risk Factors
- Clinical trial delays, patient recruitment challenges, or safety/efficacy failures could materially impair the stock.
- Quantum BioPharma may need additional capital to fund the Phase 2 trial, creating dilution risk.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3375262 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 19d ago | 6-K | $3.11 | awaiting T+20 | — | $2.32 (−25.40%) |
Oct 6, 2026 21d ago | 6-K | $3.09 | awaiting T+20 | — | $2.32 (−24.92%) |
Oct 6, 2026 21d ago | Press Release | $3.09 | awaiting T+20 | — | $2.32 (−24.92%) |
Oct 5, 2026 22d ago | SC 13G/A | $3.27 | awaiting T+20 | — | $2.32 (−29.05%) |
Sep 24, 2026 4w ago | 6-K | $4.00 $2.27 | ▼ −43.25% | ▼ −42.83% | $2.32 (−42.00%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.32 (−37.63%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.32 (−37.63%) |
Sep 15, 2026 6w ago | 6-K | $3.46 $2.89 | ▼ −16.47% | ▼ −19.45% | $2.32 (−32.95%) |
Sep 1, 2026 8w ago | 6-K | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.32 (−24.68%) |
Sep 1, 2026 8w ago | Press Release | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.32 (−24.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers